

July 2025

Dear Fellow Investor,

The table below shows performance figures for the first half of 2025 and the cumulative and annualised performance of the Fundsmith Equity Fund – a sub fund of the Fundsmith Sicav ('Fund' or 'Sicav') and various comparators. Please note the differing start dates for the various share classes, noted below the table.

% Total Return	1 st Jan to 30 th June 2025	Inception to 30 th June 2025	
		Cumulative	Annualised
Fundsmith Equity Fund EUR T Class ¹	-5.2	+508.2	+14.1
MSCI World Index EUR ²	-3.4	+414.5	+12.7
European Bonds ³	-2.3	+54.1	+3.2
Cash ⁴	+1.2	+6.8	+0.5
Fundsmith Equity Fund CHF I Class ¹	-6.0	+310.1	+11.2
MSCI World Index CHF ²	-4.0	+269.5	+10.4
Fundsmith Equity Fund USD I Class ¹	+6.8	+303.8	+12.0
MSCI World Index USD ²	+9.5	+249.6	+10.7
Fundsmith Equity Fund GBP I Class ¹	-2.3	+315.0	+13.5
MSCI World Index GBP ²	+0.1	+263.7	+12.2

¹ Accumulation Shares, net of fees, priced at 13:00 CET, launch dates, **EUR T:** 2.11.11, **CHF I:** 5.4.12, **USD I:** 13.3.13, **GBP I:** 15.4.14, source: Bloomberg. NB Prior to March 2019 performance relates to Fundsmith Equity Fund Feeder

² MSCI World Index priced at close of business US time, source: Bloomberg

³ Bloomberg Series-E Euro Govt 10+ yr Bond Index, source: Bloomberg

⁴ € Interest Rate, source: Bloomberg

The Fund is not managed with reference to any benchmark, the above comparators are provided for information purposes only.

The T Class Accumulation shares in Euros fell -5.2% in the first six months of the year, 1.8 percentage points less than what is perhaps the most obvious comparator — the MSCI World Index (€ net). (Note

we do not hedge currency exposure and so the main difference in performance between the different currency share classes is due to currency movements in the period. These currency movements also impact the performance of the comparator, MSCI World Index.)

What did well for us in the first six months of 2025? Here are the five biggest positive contributors to performance:

Stock	Attribution
Philip Morris	+1.6%
Meta Platforms	+1.1%
IDEXX	+0.6%
L'Oréal	+0.5%
Microsoft	+0.4%

Source: Northern Trust

As ever, we continue to make money with old friends.

The five biggest detractors from our Fund's performance during the period were:

Stock	Attribution
Novo Nordisk	-1.8%
LVMH	-1.1%
Waters	-0.7%
Church & Dwight	-0.7%
Alphabet	-0.6%

Source: Northern Trust

Novo Nordisk alone accounted for all the underperformance during the period. Its ability to snatch defeat from the jaws of victory in respect of its leadership in weight loss drugs continues to be remarkable. Its inability to deal with the US legal and regulatory system's approach to its success would be interesting to observe from a safe distance.

Novo is controlled by a foundation which we have seen as a strength in terms of its ability to make good long-term decisions. It has now fired its CEO. We wait with increasingly thin patience to see whom it appoints as replacement and what changes they bring.

Another adverse factor affecting our Fund's performance has been the US Dollar. The majority of the companies we invest in are based in the United States, report in US Dollars and more importantly have the majority of their revenues in this currency. Therefore the move in the Euro vs US Dollar exchange rate from \$1.04 at the beginning of the year to \$1.17 at the end of June (12% depreciation) has had a major effect. This can be seen in the fact that the US Dollar denominated share class (I Acc USD) was up by 6.8% in the first half

of 2025. I doubt this performance by the Dollar relative to the Euro is a reflection of the strength of the Eurozone economy, and in fact the USD Trade Weighted Index has fallen by around 7.5%.

I have no clue if or when this will reverse but would merely observe that the apparent policy aims of the Trump administration — reducing the US trade deficit and lowering interest rates — are incompatible with a strong Dollar. But equally the course of events in the Eurozone do not suggest to me that the Euro is likely to see continued strength either.

We prefer not to update the valuation at this stage of the year as although share prices are certain, the free cash flow ('FCF') on which we base our valuation has elements of seasonality so we will leave it until the year end to update the portfolio valuation.

During the period we began accumulating stakes in Zoetis, the animal health company, Intuit, the accounting software business and EssilorLuxottica the global eyewear manufacturer and we sold our positions in PepsiCo and Brown-Forman. As a result our portfolio turnover in the first half was 8.9% and the voluntary dealing (dealing not caused by redemptions or subscriptions) cost €0.5m during the half year (0.006% or 0.6 of a basis point). The Ongoing Charges Figure for the T Class Accumulation shares was 1.08% and with the cost of all dealing added, the Total Cost of Investment was 1.10%.

We continue to invest with the aim of long-term superior performance adjusted for risk and thank you for your continued support.

Yours sincerely,



Terry Smith
CEO
Fundsmith LLP

Disclaimer: A Key Information Document and an English language prospectus for the Fundsmith Equity Fund (Sicav) are available via the Fundsmith website or on request and investors should consult these documents before purchasing shares in the fund. Past performance is not necessarily a guide to future performance. The value of investments and the income from them may fall as well as rise and be affected by changes in exchange rates, and you may not get back the amount of your original investment. Fundsmith LLP does not offer investment advice or make any recommendations regarding the suitability of its product. This document is communicated by Fundsmith LLP which is authorised and regulated by the Financial Conduct Authority.

FundRock Management Company S.A. is a management company of undertakings for collective investment in transferable securities ("UCITS") within

the meaning of the UCITS Directive and is authorised to offer shares in the Fundsmith SICAV to investors on a cross border basis.

Fundsmith Equity Fund (Sicav), which is the subject of this document, does not relate to a collective investment scheme which is authorised under section 286 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") or Recognised under section 287 of the SFA. This document has not been registered as a prospectus with the Monetary Authority of Singapore (the "MAS"). Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of units in the Fund may not be circulated or distributed, nor may units be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than 1. To an institutional investor under section 304 of the SFA; or 2. To a relevant person pursuant to section 305(1) of the SFA or any person pursuant to section 305(2) of the SFA (and such distribution is in accordance with the conditions specified in section 305 of the SFA); or 3. Otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. In particular, for investment fund that are not authorised or recognised by the MAS, units in such funds are not allowed to be offered to the retail public. This document and any other document or material issued in connection with the offer or sale is not a prospectus as defined in the SFA. Accordingly, statutory liability under the SFA in relation to the content of prospectuses does not apply and investors should consider carefully whether the investment is suitable for them. In particular, for investment fund that are not authorised or recognised by the MAS, units in such funds are not allowed to be offered to the retail public. This document and any other document or material issued in connection with the offer or sale is not a prospectus as defined in the SFA. Accordingly, statutory liability under the SFA in relation to the content of prospectuses does not apply and investors should consider carefully whether the investment is suitable for them.

The views and opinions expressed herein are those of Fundsmith as of the date hereof and are subject to change based on prevailing market and economic conditions and will not be updated or supplemented.

Sources: Fundsmith LLP and Bloomberg unless otherwise stated.

Data is as at 30th June 2025 unless otherwise stated.

Portfolio turnover is a measure of the fund's trading activity and has been calculated by taking the total share purchases and sales less total creations and liquidations divided by the average net asset value of the fund.

The Bloomberg Series-E Euro Govt 10+ yr Bond Index shows what you might have earned if you had invested in Government Debt.

The € Interest Rate shows what you might have earned if you had invested in cash.

MSCI World Index is the exclusive property of MSCI Inc. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or final products. This report is not approved, reviewed or produced by MSCI. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor's and "GICS®" is a service mark of MSCI and Standard & Poor's.

The MSCI World Index is a developed world index of global equities across all sectors and, as such, is a fair comparison given the fund's investment objective and policy.